HPV Associated Disorders Market Size and Forecast 2024-2033|AstraZeneca plc, F. Hoffmann-La Roche Ltd, Biocon Ltd, GlaxoSmithKline plc, Merck & Co Inc

3D molecular structure of Human papillomavirus type 16, associated with various cancers and other diseases. PDB 3J6R

Overview and Scope

The human papillomavirus-associated disorders refer to a virus that can induce aberrant tissue growth such as warts and other cell abnormalities. These disorders are mainly transmitted by sexual intercourse or other forms of skin-to-skin contact. Vaccines, medication, and other diagnoses can help protect against HPV types that cure HPV cancer.

Sizing and Forecast

The hpv associated disorders market size has grown strongly in recent years. It will grow from $19.42 billion in 2023 to $20.97 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to rising prevalence of hpv-associated disorders, increasing awareness about hpv and its associated disorders, advancements in diagnostic technologies, government initiatives for hpv vaccination programs, growing demand for early screening and vaccination

The hpv associated disorders market size is expected to see strong growth in the next few years. It will grow to $27.82 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to approval of new hpv vaccines, increasing initiatives by government and private organizations for early screening and vaccination, rising incidence of cervical cancer, growing demand for non-invasive diagnostic tests, integration of hpv testing in routine healthcare. Major trends in the forecast period include development of next-generation hpv vaccines, adoption of point-of-care hpv testing, shift towards molecular techniques in hpv detection, personalized approaches in hpv management, integration of hpv testing in women’s health services.

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/hpv-associated-disorders-global-market-report

Segmentation & Regional Insights

The hpv associated disorders market covered in this report is segmented –

1) By Indication: Cervical Intraepithelial Neoplasia (CIN), Cervical Cancer, Anal Intraepithelial Neoplasia (AIN), Anal Cancer, Genital Warts, Other Indications

2) By Therapy: Prevention, Treatment

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

North America was the largest region in the HPV associated disorders market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hpv associated disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7777&type=smp

Major Driver Impacting Market Growth

Increased prevalence of HPV-related cases is expected to propel the HPV-associated disorders market. HPV-associated disorders include benign verrucae vulgates, condylomas acuminata to the malignancies of the cervix, vulva, anus, and penis, anogenital warts, recurrent respiratory papillomatosis, anogenital and oropharyngeal cancers. HPV infection has a considerable proportion worldwide, mainly in women. For instance, in January 2022, according to a report published by cancer.net, an estimated 14,100 women in the United States will be diagnosed with invasive cervical cancer, with 604,127 women worldwide diagnosed with cervical cancer in 2020. Furthermore, in 2023, an estimated 4,310 deaths occurred from cervical cancer in the United States. Therefore, an increase in the prevalence of HPV cases will drive the HPV-associated disorders market growth.

Key Industry Players

Major companies operating in the hpv associated disorders market report are AstraZeneca plc, F. Hoffmann-La Roche Ltd, Biocon Ltd, GlaxoSmithKline plc, Merck & Co Inc., Pfizer Inc., Eli Lilly and Company, Sanofi S. A., Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Celgene Corporation, Gilead Sciences Inc., Ipsen S. A., Mylan N. V., Teva Pharmaceutical Industries Ltd., Bayer AG, Eisai Co. Ltd., Genentech Inc., Medtronic plc, Novo Nordisk A/S, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, CSL Limited, Lupin Limited

The hpv associated disorders market report table of contents includes:

1. Executive Summary

2. HPV Associated Disorders Market Characteristics

3. HPV Associated Disorders Market Trends And Strategies

4. HPV Associated Disorders Market – Macro Economic Scenario

5. Global HPV Associated Disorders Market Size and Growth

26. South America HPV Associated Disorders Market

27. Brazil HPV Associated Disorders Market

28. Middle East HPV Associated Disorders Market

29. Africa HPV Associated Disorders Market

30. HPV Associated Disorders Market Competitive Landscape And Company Profiles

Top Major Players: